David T Teachey
Overview
Explore the profile of David T Teachey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
178
Citations
11602
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Narang S, Ghebrechristos Y, Evensen N, Murrell N, Jasinski S, Ostrow T, et al.
Nat Commun
. 2024 Aug;
15(1):7425.
PMID: 39198446
Relapsed pediatric B-cell acute lymphoblastic leukemia (B-ALL) remains one of the leading causes of cancer mortality in children. We performed Hi-C, ATAC-seq, and RNA-seq on 12 matched diagnosis/relapse pediatric leukemia...
12.
Bhatla T, Hogan L, Teachey D, Bautista F, Moppett J, Velasco Puyo P, et al.
Blood
. 2024 Aug;
144(21):2237-2247.
PMID: 39158071
Patients with relapsed/refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) have poor outcomes compared with newly diagnosed, treatment-naïve patients. The phase 2, open-label DELPHINUS study evaluated daratumumab (16 mg/kg...
13.
Polonen P, Di Giacomo D, Seffernick A, Elsayed A, Kimura S, Benini F, et al.
Nature
. 2024 Aug;
632(8027):1082-1091.
PMID: 39143224
T-lineage acute lymphoblastic leukaemia (T-ALL) is a high-risk tumour that has eluded comprehensive genomic characterization, which is partly due to the high frequency of noncoding genomic alterations that result in...
14.
Seffernick A, Cao X, Cheng C, Yang W, Autry R, Yang J, et al.
bioRxiv
. 2024 Aug;
PMID: 39131398
Motivation: Large datasets containing multiple clinical and omics measurements for each subject motivate the development of new statistical methods to integrate these data to advance scientific discovery. Model: We propose...
15.
Patel R, Ghilardi G, Zhang Y, Chiang Y, Xie W, Guruprasad P, et al.
Sci Immunol
. 2024 Jul;
9(97):eadn6509.
PMID: 39028827
Most patients treated with US Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid...
16.
Hughes A, Teachey D, Diorio C
Semin Immunopathol
. 2024 Jul;
46(3-4):5.
PMID: 39012374
The advent of chimeric antigen receptor T cells (CAR-T) has been a paradigm shift in cancer immunotherapeutics, with remarkable outcomes reported for a growing catalog of malignancies. While CAR-T are...
17.
Lindell R, Sayed S, Campos J, Knight M, Mauracher A, Hay C, et al.
medRxiv
. 2024 Jul;
PMID: 38946991
Sepsis is the leading cause of death of hospitalized children worldwide. Despite the established link between immune dysregulation and mortality in pediatric sepsis, it remains unclear which host immune factors...
18.
Kimura S, Park C, Montefiori L, Iacobucci I, Polonen P, Gao Q, et al.
Cancer Discov
. 2024 Jun;
14(10):1838-1859.
PMID: 38916500
Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand...
19.
Diorio C, Hernandez-Miyares L, Espinoza D, Banwell B, Bar-Or A, DiNofia A, et al.
Blood
. 2024 Jun;
144(13):1387-1398.
PMID: 38905637
Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common but potentially severe adverse event associated with chimeric antigen receptor T-cell (CART) therapy, characterized by the development of acute neurologic symptoms...
20.
Hayashi R, Hermiston M, Wood B, Teachey D, Devidas M, Chen Z, et al.
Blood
. 2024 Mar;
143(20):2053-2058.
PMID: 38457359
Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a Children's Oncology Group phase 3 clinical trial for newly diagnosed patients with T acute lymphoblastic leukemia or...